Mehdi Razavi, MD
Clinical Cardiac Electrophysiology · Houston, TXNPI 1598867749
Payments from drug & device makers
Across 547 payments — averaging $713.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Irhythm Technologies, Inc.$202K
- Saranas, Inc.$113K
- Biosense Webster, Inc.$30K
- Boston Scientific$21K
- Medical Device Business Services, Inc.$11K
- Abbott$8K
- plus $6K from 28 others
What the payments were for
- Consulting fees$205,38057%
- Speaking & faculty fees$130,52136%
- Travel & lodging$2,9171%
- Food & beverage$16,7935%
- Education$2,5001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Irhythm Technologies, Inc. | 52 | $202,117 |
| Saranas, Inc. | 10 | $112,519 |
| Biosense Webster, Inc. | 155 | $30,397 |
| Boston Scientific | 93 | $20,611 |
| Medical Device Business Services, Inc. | 3 | $10,700 |
| Abbott | 110 | $7,780 |
| Lightforce Orthodontics, Inc. | 5 | $2,702 |
| Medtronic(2 entities) | 34 | $1,042 |
| Impulse Dynamics (USA) Inc. | 15 | $823 |
| Pfizer | 12 | $217 |
| Abiomed | 2 | $188 |
| Cardiva Medical, Inc. | 7 | $145 |
| Biotronik Inc. | 5 | $118 |
| Johnson & Johnson | 6 | $111 |
| Novartis | 5 | $98 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| Elutia, Inc. | 4 | $81 |
| Novo Nordisk | 3 | $66 |
| Baxter Healthcare | 3 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Evoke Pharma, Inc. | 2 | $35 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $33 |
| Bardy Diagnostics, Inc. | 1 | $30 |
| Itamar Medical Inc | 1 | $29 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Bard Access Systems, Inc. | 1 | $21 |
| Circa Scientific, Inc. | 1 | $20 |
| Cvrx, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Haemonetics Corporation | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZIO XT Patch$105,000
- ZIO Patch$96,980
- VersaCross Access Solution$12,750
- Carto 3$7,952
- Rhythmia Mapping System$5,500
- LIGHTFORCE ORTHODONTIC SYSTEM$2,500
- AVEIR$1,481
- Cardiac Mapping System$1,120
- MERLIN@HOME$836
- Carto 3 System$683
- OPTIMIZER$637
- ENSITE PRECISION$500
- GALLANT$464
- Confirm Rx$292
- Advisa$280
- RHYTHMIA$259
- Micra$255
- EnSite Precision Cardiac Mapping System$188
- QUADRA ASSURA$179
- ViewMate Intracardiac Echo$159
How this compares
$390,238 in reported general payments places this provider in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $217,463 |
| XareltoRivaroxaban | 47 | $54,241 |
| MultaqDronedarone Hcl | 31 | $35,643 |
| CorlanorIvabradine Hcl | 11 | $6,422 |
| Flecainide Acetate | 91 | $5,433 |
| Propafenone Hcl | 37 | $1,822 |
| Metoprolol Succinate | 104 | $1,392 |
| Mexiletine Hcl | 18 | $1,163 |
| Amiodarone Hcl | 33 | $956 |
| Losartan Potassium | 42 | $694 |
| Amlodipine Besylate | 60 | $602 |
| Atorvastatin Calcium | 57 | $503 |
| Potassium Chloride | 15 | $273 |
| Metoprolol Tartrate | 46 | $261 |
| Lisinopril | 28 | $236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $217 | $217,463204 claims |
| Johnson & JohnsonXarelto | $111 | $54,24147 claims |
| Sanofi-aventis U.S. LLCMultaq | $52 | $35,64331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Houston
- Miguel ValderrabanoHouston$1.3M
- Ramesh HariharanHouston$793K
- Abdi RasekhHouston$728K
- Amir AzeemHouston$488K
- Ilyas ColombowalaHouston$362K
- Ijeoma EkeruoHouston$353K
- John SegerHouston$300K
- Mihail CheluHouston$256K
- Jie ChengHouston$176K
- Nadim NasirHouston$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.